James Stewart loves being active. He enjoys rollerblading and paddle boarding. He jumps off cliffs and bridges into lakes. "I had never been sick a day in my life," said Stewart, who lives in Round ...
The European Medicines Agency has recommended granting a conditional marketing authorization for ImmunityBio, Inc.‘s (NASDAQ: IBRX) Anktiva (nogapendekin alfa inbakicept) in combination with Bacillus ...
Shares of ImmunityBio ticked higher after the company said the European Medicines Agency recommended granting a conditional marketing authorization for its treatment for non-muscle invasive bladder ...
TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, consistent release of chemotherapy proved far more effective than traditional ...
The FDA has approved Pfizer and Astellas’ Padcev (enfortumab vedotin-ejfv) plus Merck’s Keytruda (pembrolizumab) as a perioperative treatment for adults with muscle-invasive bladder cancer who are ...
What Is Keytruda/Padcev Combination Therapy, and Why Does It Matter? The FDA has approved a new combination therapy that uses two different types of anticancer medicines for treating adults with ...
Editor's Note: This is an excerpt from WBUR's weekly health newsletter, CommonHealth. If you like what you read and want it in your inbox, sign up here. Bladder cancer hits men especially hard. The ...
A cohort analysis of patients treated with RC for MIBC across the United States was performed using the National Cancer Database. The primary outcome measure was overall survival (OS), defined as the ...
An experimental treatment method has shown promise in fighting a hard-to-treat form of bladder cancer known as BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC). BCG (Bacillus ...
(RTTNews) - enGene Holdings Inc. (ENGN) jumped 53.08% to $9.20, up $3.19, after its press release showing that its gene-therapy candidate detalimogene achieved a 62% complete response rate at six ...
Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results